Does Presence of Persistent Molecular Mutations Matter in AML Patients Undergoing Allogeneic Stem Cell Transplant?

Authors

Usama Gergis MD, MBA, Lehigh Valley Health NetworkFollow

Publication/Presentation Date

3-2019

Volume

25

Issue

3

Published In/Presented At

10.1016/j.bbmt.2018.12.386

Disciplines

Medicine and Health Sciences

Department(s)

Department of Medicine, Hematology-Medical Oncology Division, Lehigh Valley Topper Cancer Institute

Document Type

Article